BEVERLY, MA–(Marketwired – June 03, 2015) - Cellceutix Corporation (OTC: CTIX) (the “Company”), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to provide shareholders insight to our presentation of certain clinical data at the annual American Society of Clinical Oncology (ASCO) meeting in Chicago that concluded on Tuesday, June 2, 2015.
Cellceutix’s poster provided an overview of the Company’s ongoing Phase 1 clinical trial to evaluate the safety and preliminary efficacy of Kevetrin as a monotherapy (single-agent treatment) for patients with advanced solid tumors. The study has demonstrated the safety of Kevetrin administration over repeated cycles. In addition, increases in p21 expression were shown in a number of the patients in multiple cancers and p21 activity appears to be dose related. Cellceutix showed that Kevetrin may become an important therapy in the treatment of gynecological cancers/ovarian cancers.
The poster was visited by industry and academia, including key opinion leaders, representatives of large and small pharmaceutical companies, leading universities, foundations and leading international cancer scientists interested in information on Kevetrin and its ability to act upon p53, an important therapeutic target in oncology as a master regulator of the cell cycle.
Cellceutix is developing Kevetrin as a monotherapy due to its unique mechanism of action to help restore p53 function. The objective of the therapy is to trigger the natural responses of apoptosis, or programmed cell death, and cell cycle arrest. Combined with its favorable safety and pharmacokinetic profile, Kevetrin is a strong candidate not only as a potential stand-alone therapy, but also in combination with other treatments, including immunotherapies, as part of the next generation in cancer care.
“The Cellceutix poster at ASCO brought great interest to Kevetrin with data suggesting that Kevetrin can reactivate p53 with very limited toxicity as a front-line treatment for cancer,” stated Dr. Krishna Menon, Cellceutix Chief Scientific Officer. “Although the framework of the trial and ASCO guidelines prevented us from disclosing certain information, these experienced scientists took note of the gynecological cancer patients in the trial and extrapolated the data to pose many questions. Several companies and institutions wanted to discuss the possibility of Kevetrin in combination with their drugs or therapies to potentially increase efficacy and reduce or avoid side effects in a variety of cancers, including some rare, hard-to-treat and pediatric cancers. This is akin to the Kevetrin and sunitinib combination tested in a renal cancer line that generated very optimistic results. Kevetrin will continue to be developed in collaborations to become the compound of choice for the treatment of many cancers.”